ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
-0.56 (-2.66%)
Real-time:   1:05PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.90 - 21.12
52 week 11.26 - 32.00
Open 20.97
Vol / Avg. 1.46M/2.48M
Mkt cap 2.02B
P/E     -
Div/yield     -
EPS -0.44
Shares 98.46M
Beta 3.16
Inst. own 85%
Jun 2, 2014
ACADIA Pharmaceuticals Annual Shareholder Meeting (Estimated) Add to calendar
May 5, 2014
Q1 2014 ACADIA Pharmaceuticals Earnings Release (Estimated) Add to calendar
Apr 8, 2014
ACADIA Pharmaceuticals at Needham Healthcare Conference - Webcast
Mar 10, 2014
ACADIA Pharmaceuticals at ROTH Conference - Webcast
Mar 5, 2014
ACADIA Pharmaceuticals at Cowen Health Care Conference - Webcast
Feb 27, 2014
Q4 2013 ACADIA Pharmaceuticals Earnings Conference Call - Webcast
Feb 27, 2014
Q4 2013 ACADIA Pharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -32564.87% -3314.24%
Operating margin -32875.68% -3344.72%
EBITD margin - -3337.82%
Return on average assets -24.89% -25.49%
Return on average equity -26.64% -28.41%
Employees 48 -
CDP Score - -


United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Uli Hacksell Ph.D. President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
Bio & Compensation  - Reuters
Thomas H. Aasen Chief Financial Officer, Chief Business Officer, Executive Vice President, Treasurer
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Roger M. Mills M.D. Executive Vice President - Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Glenn F. Baity Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 42
Bio & Compensation  - Reuters
Michael T. Borer Independent Director
Age: 54
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 55
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters